JP2000510460A - スクアラミンを他の抗癌剤と併用する上皮性悪性腫瘍の治療 - Google Patents
スクアラミンを他の抗癌剤と併用する上皮性悪性腫瘍の治療Info
- Publication number
- JP2000510460A JP2000510460A JP09539076A JP53907697A JP2000510460A JP 2000510460 A JP2000510460 A JP 2000510460A JP 09539076 A JP09539076 A JP 09539076A JP 53907697 A JP53907697 A JP 53907697A JP 2000510460 A JP2000510460 A JP 2000510460A
- Authority
- JP
- Japan
- Prior art keywords
- squalamine
- treatment
- tumor
- cytotoxic compound
- cytotoxic
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- UIRKNQLZZXALBI-MSVGPLKSSA-N Squalamine Chemical compound C([C@@H]1C[C@H]2O)[C@@H](NCCCNCCCCN)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@H](C)CC[C@H](C(C)C)OS(O)(=O)=O)[C@@]2(C)CC1 UIRKNQLZZXALBI-MSVGPLKSSA-N 0.000 title claims abstract description 204
- UIRKNQLZZXALBI-UHFFFAOYSA-N Squalamine Natural products OC1CC2CC(NCCCNCCCCN)CCC2(C)C2C1C1CCC(C(C)CCC(C(C)C)OS(O)(=O)=O)C1(C)CC2 UIRKNQLZZXALBI-UHFFFAOYSA-N 0.000 title claims abstract description 203
- 229950001248 squalamine Drugs 0.000 title claims abstract description 203
- 206010028980 Neoplasm Diseases 0.000 title claims abstract description 108
- 238000011282 treatment Methods 0.000 title claims abstract description 106
- 239000002246 antineoplastic agent Substances 0.000 title description 8
- 230000036210 malignancy Effects 0.000 title description 5
- 229940041181 antineoplastic drug Drugs 0.000 title description 2
- 238000000034 method Methods 0.000 claims abstract description 62
- 150000001875 compounds Chemical class 0.000 claims abstract description 44
- 231100000433 cytotoxic Toxicity 0.000 claims abstract description 40
- 230000001472 cytotoxic effect Effects 0.000 claims abstract description 40
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 claims abstract description 18
- 229960004397 cyclophosphamide Drugs 0.000 claims abstract description 18
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 claims abstract description 17
- 229960004316 cisplatin Drugs 0.000 claims abstract description 16
- DLGOEMSEDOSKAD-UHFFFAOYSA-N Carmustine Chemical compound ClCCNC(=O)N(N=O)CCCl DLGOEMSEDOSKAD-UHFFFAOYSA-N 0.000 claims abstract description 13
- -1 BCNU) Chemical compound 0.000 claims abstract description 8
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 claims abstract description 8
- 229930012538 Paclitaxel Natural products 0.000 claims abstract description 7
- 229960001592 paclitaxel Drugs 0.000 claims abstract description 7
- 230000005855 radiation Effects 0.000 claims abstract description 7
- KRHYYFGTRYWZRS-UHFFFAOYSA-M Fluoride anion Chemical compound [F-] KRHYYFGTRYWZRS-UHFFFAOYSA-M 0.000 claims abstract description 5
- 229940035893 uracil Drugs 0.000 claims abstract description 5
- 206010006187 Breast cancer Diseases 0.000 claims description 14
- 208000026310 Breast neoplasm Diseases 0.000 claims description 14
- 208000025997 central nervous system neoplasm Diseases 0.000 claims description 11
- 238000002347 injection Methods 0.000 claims description 9
- 239000007924 injection Substances 0.000 claims description 9
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 8
- 201000005202 lung cancer Diseases 0.000 claims description 8
- 208000020816 lung neoplasm Diseases 0.000 claims description 8
- 229940045719 antineoplastic alkylating agent nitrosoureas Drugs 0.000 claims description 5
- 108010006654 Bleomycin Proteins 0.000 claims description 3
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 claims description 3
- FOCVUCIESVLUNU-UHFFFAOYSA-N Thiotepa Chemical compound C1CN1P(N1CC1)(=S)N1CC1 FOCVUCIESVLUNU-UHFFFAOYSA-N 0.000 claims description 3
- 229960001561 bleomycin Drugs 0.000 claims description 3
- OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 claims description 3
- VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 claims description 3
- 229960005420 etoposide Drugs 0.000 claims description 3
- 229960000390 fludarabine Drugs 0.000 claims description 3
- GIUYCYHIANZCFB-FJFJXFQQSA-N fludarabine phosphate Chemical compound C1=NC=2C(N)=NC(F)=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@@H]1O GIUYCYHIANZCFB-FJFJXFQQSA-N 0.000 claims description 3
- 229960000485 methotrexate Drugs 0.000 claims description 3
- CPTBDICYNRMXFX-UHFFFAOYSA-N procarbazine Chemical compound CNNCC1=CC=C(C(=O)NC(C)C)C=C1 CPTBDICYNRMXFX-UHFFFAOYSA-N 0.000 claims description 3
- 229960000624 procarbazine Drugs 0.000 claims description 3
- 229960001196 thiotepa Drugs 0.000 claims description 3
- 229960004528 vincristine Drugs 0.000 claims description 3
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 claims description 3
- OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 claims description 3
- GBABOYUKABKIAF-GHYRFKGUSA-N vinorelbine Chemical compound C1N(CC=2C3=CC=CC=C3NC=22)CC(CC)=C[C@H]1C[C@]2(C(=O)OC)C1=CC([C@]23[C@H]([C@]([C@H](OC(C)=O)[C@]4(CC)C=CCN([C@H]34)CC2)(O)C(=O)OC)N2C)=C2C=C1OC GBABOYUKABKIAF-GHYRFKGUSA-N 0.000 claims description 3
- 229960002066 vinorelbine Drugs 0.000 claims description 3
- ATJFFYVFTNAWJD-UHFFFAOYSA-N Tin Chemical compound [Sn] ATJFFYVFTNAWJD-UHFFFAOYSA-N 0.000 claims description 2
- SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 claims description 2
- 229960005277 gemcitabine Drugs 0.000 claims description 2
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 claims 4
- HOMGKSMUEGBAAB-UHFFFAOYSA-N ifosfamide Chemical compound ClCCNP1(=O)OCCCN1CCCl HOMGKSMUEGBAAB-UHFFFAOYSA-N 0.000 claims 2
- 229960001101 ifosfamide Drugs 0.000 claims 2
- 229960004857 mitomycin Drugs 0.000 claims 2
- KKZJGLLVHKMTCM-UHFFFAOYSA-N mitoxantrone Chemical compound O=C1C2=C(O)C=CC(O)=C2C(=O)C2=C1C(NCCNCCO)=CC=C2NCCNCCO KKZJGLLVHKMTCM-UHFFFAOYSA-N 0.000 claims 2
- 229960001156 mitoxantrone Drugs 0.000 claims 2
- 201000011510 cancer Diseases 0.000 abstract description 21
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 abstract description 6
- 239000012830 cancer therapeutic Substances 0.000 abstract description 5
- OSTGTTZJOCZWJG-UHFFFAOYSA-N nitrosourea Chemical compound NC(=O)N=NO OSTGTTZJOCZWJG-UHFFFAOYSA-N 0.000 abstract description 4
- 229940009456 adriamycin Drugs 0.000 abstract description 2
- 230000000977 initiatory effect Effects 0.000 abstract description 2
- 238000010253 intravenous injection Methods 0.000 abstract description 2
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 abstract 2
- 229910052697 platinum Inorganic materials 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 description 66
- 230000000694 effects Effects 0.000 description 47
- 102100022897 Sodium/hydrogen exchanger 10 Human genes 0.000 description 29
- 230000033115 angiogenesis Effects 0.000 description 27
- 210000002889 endothelial cell Anatomy 0.000 description 24
- 238000002474 experimental method Methods 0.000 description 23
- 210000004204 blood vessel Anatomy 0.000 description 22
- 210000004087 cornea Anatomy 0.000 description 20
- 241000283973 Oryctolagus cuniculus Species 0.000 description 19
- 239000003814 drug Substances 0.000 description 13
- 230000012010 growth Effects 0.000 description 13
- 239000003102 growth factor Substances 0.000 description 13
- 238000001959 radiotherapy Methods 0.000 description 13
- 206010018338 Glioma Diseases 0.000 description 12
- 241001465754 Metazoa Species 0.000 description 12
- 241000700159 Rattus Species 0.000 description 12
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 12
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 12
- 239000003112 inhibitor Substances 0.000 description 12
- 230000005764 inhibitory process Effects 0.000 description 12
- 238000012360 testing method Methods 0.000 description 12
- 102000003669 Antiporters Human genes 0.000 description 11
- 108090000084 Antiporters Proteins 0.000 description 11
- 230000002401 inhibitory effect Effects 0.000 description 11
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 10
- 108091006647 SLC9A1 Proteins 0.000 description 10
- 102100030980 Sodium/hydrogen exchanger 1 Human genes 0.000 description 10
- 239000004037 angiogenesis inhibitor Substances 0.000 description 10
- 230000001772 anti-angiogenic effect Effects 0.000 description 10
- 229940079593 drug Drugs 0.000 description 10
- 239000011734 sodium Substances 0.000 description 10
- 229910052708 sodium Inorganic materials 0.000 description 10
- 208000032612 Glial tumor Diseases 0.000 description 9
- 210000004556 brain Anatomy 0.000 description 9
- 238000007912 intraperitoneal administration Methods 0.000 description 9
- 238000001990 intravenous administration Methods 0.000 description 9
- 239000000203 mixture Substances 0.000 description 9
- 239000008194 pharmaceutical composition Substances 0.000 description 9
- 230000035755 proliferation Effects 0.000 description 9
- 210000001519 tissue Anatomy 0.000 description 9
- XSDQTOBWRPYKKA-UHFFFAOYSA-N amiloride Chemical compound NC(=N)NC(=O)C1=NC(Cl)=C(N)N=C1N XSDQTOBWRPYKKA-UHFFFAOYSA-N 0.000 description 8
- 238000003556 assay Methods 0.000 description 8
- 230000015572 biosynthetic process Effects 0.000 description 8
- 230000037396 body weight Effects 0.000 description 8
- 238000002512 chemotherapy Methods 0.000 description 8
- 238000011161 development Methods 0.000 description 8
- 230000018109 developmental process Effects 0.000 description 8
- 230000008569 process Effects 0.000 description 8
- 230000002829 reductive effect Effects 0.000 description 8
- 239000000126 substance Substances 0.000 description 8
- 230000002792 vascular Effects 0.000 description 8
- 241000699670 Mus sp. Species 0.000 description 7
- 229960002576 amiloride Drugs 0.000 description 7
- 230000002491 angiogenic effect Effects 0.000 description 7
- 201000010099 disease Diseases 0.000 description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 7
- 238000009826 distribution Methods 0.000 description 7
- 229920000642 polymer Polymers 0.000 description 7
- 239000000758 substrate Substances 0.000 description 7
- 238000001356 surgical procedure Methods 0.000 description 7
- 230000004083 survival effect Effects 0.000 description 7
- 208000003174 Brain Neoplasms Diseases 0.000 description 6
- 102000001708 Protein Isoforms Human genes 0.000 description 6
- 108010029485 Protein Isoforms Proteins 0.000 description 6
- 108091006650 SLC9A2 Proteins 0.000 description 6
- 102100030382 Sodium/hydrogen exchanger 2 Human genes 0.000 description 6
- 230000004663 cell proliferation Effects 0.000 description 6
- 239000003795 chemical substances by application Substances 0.000 description 6
- 229940127089 cytotoxic agent Drugs 0.000 description 6
- 230000002354 daily effect Effects 0.000 description 6
- 230000001419 dependent effect Effects 0.000 description 6
- 229940028435 intralipid Drugs 0.000 description 6
- 239000008188 pellet Substances 0.000 description 6
- 210000004881 tumor cell Anatomy 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- 206010061218 Inflammation Diseases 0.000 description 5
- BWZOPYPOZJBVLQ-UHFFFAOYSA-K aluminium glycinate Chemical compound O[Al+]O.NCC([O-])=O BWZOPYPOZJBVLQ-UHFFFAOYSA-K 0.000 description 5
- 238000010171 animal model Methods 0.000 description 5
- 210000003169 central nervous system Anatomy 0.000 description 5
- 210000002744 extracellular matrix Anatomy 0.000 description 5
- 230000004054 inflammatory process Effects 0.000 description 5
- 230000007246 mechanism Effects 0.000 description 5
- 238000007920 subcutaneous administration Methods 0.000 description 5
- 238000002560 therapeutic procedure Methods 0.000 description 5
- 230000004614 tumor growth Effects 0.000 description 5
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 4
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 4
- 206010027476 Metastases Diseases 0.000 description 4
- 102100032709 Potassium-transporting ATPase alpha chain 2 Human genes 0.000 description 4
- 108010083204 Proton Pumps Proteins 0.000 description 4
- 239000004480 active ingredient Substances 0.000 description 4
- 239000000969 carrier Substances 0.000 description 4
- 230000010261 cell growth Effects 0.000 description 4
- 239000002254 cytotoxic agent Substances 0.000 description 4
- 231100000599 cytotoxic agent Toxicity 0.000 description 4
- 238000009792 diffusion process Methods 0.000 description 4
- 238000000338 in vitro Methods 0.000 description 4
- 230000002062 proliferating effect Effects 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 208000010507 Adenocarcinoma of Lung Diseases 0.000 description 3
- 125000001433 C-terminal amino-acid group Chemical group 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 101000702479 Homo sapiens Sodium/hydrogen exchanger 1 Proteins 0.000 description 3
- 101000702450 Homo sapiens Sodium/hydrogen exchanger 3 Proteins 0.000 description 3
- 102000003855 L-lactate dehydrogenase Human genes 0.000 description 3
- 108700023483 L-lactate dehydrogenases Proteins 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 229920001577 copolymer Polymers 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 102000052674 human SLC9A1 Human genes 0.000 description 3
- 102000054754 human SLC9A3 Human genes 0.000 description 3
- 238000007918 intramuscular administration Methods 0.000 description 3
- 201000005249 lung adenocarcinoma Diseases 0.000 description 3
- 208000037841 lung tumor Diseases 0.000 description 3
- 239000003226 mitogen Substances 0.000 description 3
- 230000009707 neogenesis Effects 0.000 description 3
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 238000002054 transplantation Methods 0.000 description 3
- 238000011144 upstream manufacturing Methods 0.000 description 3
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 2
- 206010003571 Astrocytoma Diseases 0.000 description 2
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 2
- 241000283690 Bos taurus Species 0.000 description 2
- 108010078791 Carrier Proteins Proteins 0.000 description 2
- 108010086832 Chloride-Bicarbonate Antiporters Proteins 0.000 description 2
- 102000006786 Chloride-Bicarbonate Antiporters Human genes 0.000 description 2
- 206010012689 Diabetic retinopathy Diseases 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 2
- 239000005977 Ethylene Substances 0.000 description 2
- 102100021866 Hepatocyte growth factor Human genes 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 206010027458 Metastases to lung Diseases 0.000 description 2
- 241001529936 Murinae Species 0.000 description 2
- 206010029113 Neovascularisation Diseases 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- 238000009098 adjuvant therapy Methods 0.000 description 2
- 150000001408 amides Chemical class 0.000 description 2
- 235000001014 amino acid Nutrition 0.000 description 2
- 150000001413 amino acids Chemical group 0.000 description 2
- 239000003708 ampul Substances 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 238000004873 anchoring Methods 0.000 description 2
- 229940121369 angiogenesis inhibitor Drugs 0.000 description 2
- 230000003527 anti-angiogenesis Effects 0.000 description 2
- 229940045985 antineoplastic platinum compound Drugs 0.000 description 2
- 210000002469 basement membrane Anatomy 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 230000015624 blood vessel development Effects 0.000 description 2
- 229940044683 chemotherapy drug Drugs 0.000 description 2
- 230000002860 competitive effect Effects 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 231100000517 death Toxicity 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 230000003111 delayed effect Effects 0.000 description 2
- 239000008121 dextrose Substances 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 230000009931 harmful effect Effects 0.000 description 2
- 238000002513 implantation Methods 0.000 description 2
- 230000001976 improved effect Effects 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 231100000021 irritant Toxicity 0.000 description 2
- 239000002085 irritant Substances 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 201000001441 melanoma Diseases 0.000 description 2
- 210000004379 membrane Anatomy 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 230000009401 metastasis Effects 0.000 description 2
- 235000016709 nutrition Nutrition 0.000 description 2
- 230000035764 nutrition Effects 0.000 description 2
- 150000003058 platinum compounds Chemical class 0.000 description 2
- 230000002980 postoperative effect Effects 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 235000018102 proteins Nutrition 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- 239000000523 sample Substances 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 239000008223 sterile water Substances 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- 230000002194 synthesizing effect Effects 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000005747 tumor angiogenesis Effects 0.000 description 2
- 230000005748 tumor development Effects 0.000 description 2
- 239000003981 vehicle Substances 0.000 description 2
- GHPYJLCQYMAXGG-WCCKRBBISA-N (2R)-2-amino-3-(2-boronoethylsulfanyl)propanoic acid hydrochloride Chemical compound Cl.N[C@@H](CSCCB(O)O)C(O)=O GHPYJLCQYMAXGG-WCCKRBBISA-N 0.000 description 1
- VEEGZPWAAPPXRB-BJMVGYQFSA-N (3e)-3-(1h-imidazol-5-ylmethylidene)-1h-indol-2-one Chemical compound O=C1NC2=CC=CC=C2\C1=C/C1=CN=CN1 VEEGZPWAAPPXRB-BJMVGYQFSA-N 0.000 description 1
- 125000000143 2-carboxyethyl group Chemical group [H]OC(=O)C([H])([H])C([H])([H])* 0.000 description 1
- 125000001340 2-chloroethyl group Chemical group [H]C([H])(Cl)C([H])([H])* 0.000 description 1
- 208000003200 Adenoma Diseases 0.000 description 1
- 241000427202 Adria Species 0.000 description 1
- 201000004384 Alopecia Diseases 0.000 description 1
- 206010003694 Atrophy Diseases 0.000 description 1
- 102000019025 Calcium-Calmodulin-Dependent Protein Kinases Human genes 0.000 description 1
- 108010026870 Calcium-Calmodulin-Dependent Protein Kinases Proteins 0.000 description 1
- 102000014914 Carrier Proteins Human genes 0.000 description 1
- 241000251730 Chondrichthyes Species 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 102000003974 Fibroblast growth factor 2 Human genes 0.000 description 1
- 108090000379 Fibroblast growth factor 2 Proteins 0.000 description 1
- 102000016359 Fibronectins Human genes 0.000 description 1
- 108010067306 Fibronectins Proteins 0.000 description 1
- 102000020897 Formins Human genes 0.000 description 1
- 108091022623 Formins Proteins 0.000 description 1
- 108060003393 Granulin Proteins 0.000 description 1
- 108090000100 Hepatocyte Growth Factor Proteins 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 238000012404 In vitro experiment Methods 0.000 description 1
- 108010083687 Ion Pumps Proteins 0.000 description 1
- 102000006835 Lamins Human genes 0.000 description 1
- 108010047294 Lamins Proteins 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- 206010050017 Lung cancer metastatic Diseases 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 238000000585 Mann–Whitney U test Methods 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 241000699660 Mus musculus Species 0.000 description 1
- OKIZCWYLBDKLSU-UHFFFAOYSA-M N,N,N-Trimethylmethanaminium chloride Chemical compound [Cl-].C[N+](C)(C)C OKIZCWYLBDKLSU-UHFFFAOYSA-M 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 208000037273 Pathologic Processes Diseases 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 102000003923 Protein Kinase C Human genes 0.000 description 1
- 108090000315 Protein Kinase C Proteins 0.000 description 1
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 1
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- 108091006655 SLC9A4 Proteins 0.000 description 1
- 108091006654 SLC9A5 Proteins 0.000 description 1
- 206010041067 Small cell lung cancer Diseases 0.000 description 1
- 102000052126 Sodium-Hydrogen Exchangers Human genes 0.000 description 1
- 108010006431 Sodium-Potassium-Exchanging ATPase Proteins 0.000 description 1
- 102000005393 Sodium-Potassium-Exchanging ATPase Human genes 0.000 description 1
- 102100030707 Sodium/hydrogen exchanger 4 Human genes 0.000 description 1
- 102100029973 Sodium/hydrogen exchanger 5 Human genes 0.000 description 1
- 108091006672 Sodium–hydrogen antiporter Proteins 0.000 description 1
- 241000782099 Squaliformes Species 0.000 description 1
- 241000251778 Squalus acanthias Species 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 1
- JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 229940100198 alkylating agent Drugs 0.000 description 1
- 239000002168 alkylating agent Substances 0.000 description 1
- 230000003281 allosteric effect Effects 0.000 description 1
- 235000019270 ammonium chloride Nutrition 0.000 description 1
- 206010002224 anaplastic astrocytoma Diseases 0.000 description 1
- 238000011122 anti-angiogenic therapy Methods 0.000 description 1
- 229940034982 antineoplastic agent Drugs 0.000 description 1
- 230000037444 atrophy Effects 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000008499 blood brain barrier function Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 210000001218 blood-brain barrier Anatomy 0.000 description 1
- 208000012851 brain cyst Diseases 0.000 description 1
- 210000000133 brain stem Anatomy 0.000 description 1
- 210000005013 brain tissue Anatomy 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- VYWQZAARVNRSTR-UHFFFAOYSA-N butalamine Chemical compound O1C(NCCN(CCCC)CCCC)=NC(C=2C=CC=CC=2)=N1 VYWQZAARVNRSTR-UHFFFAOYSA-N 0.000 description 1
- 229960003756 butalamine Drugs 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 239000003560 cancer drug Substances 0.000 description 1
- 210000001043 capillary endothelial cell Anatomy 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 229960005243 carmustine Drugs 0.000 description 1
- 230000020411 cell activation Effects 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 230000032823 cell division Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 239000013043 chemical agent Substances 0.000 description 1
- 210000003837 chick embryo Anatomy 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- 229910017052 cobalt Inorganic materials 0.000 description 1
- 239000010941 cobalt Substances 0.000 description 1
- GUTLYIVDDKVIGB-UHFFFAOYSA-N cobalt atom Chemical compound [Co] GUTLYIVDDKVIGB-UHFFFAOYSA-N 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 238000011284 combination treatment Methods 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 239000013068 control sample Substances 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 238000011393 cytotoxic chemotherapy Methods 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 229960004679 doxorubicin Drugs 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 235000013601 eggs Nutrition 0.000 description 1
- 230000013020 embryo development Effects 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 238000005538 encapsulation Methods 0.000 description 1
- 230000003511 endothelial effect Effects 0.000 description 1
- 210000003989 endothelium vascular Anatomy 0.000 description 1
- 239000002702 enteric coating Substances 0.000 description 1
- 238000009505 enteric coating Methods 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 238000013401 experimental design Methods 0.000 description 1
- 238000013213 extrapolation Methods 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- TZBJGXHYKVUXJN-UHFFFAOYSA-N genistein Chemical compound C1=CC(O)=CC=C1C1=COC2=CC(O)=CC(O)=C2C1=O TZBJGXHYKVUXJN-UHFFFAOYSA-N 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 239000003324 growth hormone secretagogue Substances 0.000 description 1
- 230000009036 growth inhibition Effects 0.000 description 1
- 239000003966 growth inhibitor Substances 0.000 description 1
- 208000024963 hair loss Diseases 0.000 description 1
- 230000003676 hair loss Effects 0.000 description 1
- 238000010562 histological examination Methods 0.000 description 1
- 230000013632 homeostatic process Effects 0.000 description 1
- 238000001794 hormone therapy Methods 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- GPRLSGONYQIRFK-UHFFFAOYSA-N hydron Chemical compound [H+] GPRLSGONYQIRFK-UHFFFAOYSA-N 0.000 description 1
- 238000010874 in vitro model Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 102000006495 integrins Human genes 0.000 description 1
- 108010044426 integrins Proteins 0.000 description 1
- 210000004347 intestinal mucosa Anatomy 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 208000030776 invasive breast carcinoma Diseases 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 208000028867 ischemia Diseases 0.000 description 1
- 206010023332 keratitis Diseases 0.000 description 1
- 210000005053 lamin Anatomy 0.000 description 1
- 208000003849 large cell carcinoma Diseases 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 238000002690 local anesthesia Methods 0.000 description 1
- 238000011866 long-term treatment Methods 0.000 description 1
- 210000003141 lower extremity Anatomy 0.000 description 1
- 201000002037 lung adenoma Diseases 0.000 description 1
- 239000008176 lyophilized powder Substances 0.000 description 1
- 208000002780 macular degeneration Diseases 0.000 description 1
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
- 239000001095 magnesium carbonate Substances 0.000 description 1
- 229910000021 magnesium carbonate Inorganic materials 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 208000030883 malignant astrocytoma Diseases 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 210000001161 mammalian embryo Anatomy 0.000 description 1
- 238000007726 management method Methods 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- OCSMOTCMPXTDND-OUAUKWLOSA-N marimastat Chemical compound CNC(=O)[C@H](C(C)(C)C)NC(=O)[C@H](CC(C)C)[C@H](O)C(=O)NO OCSMOTCMPXTDND-OUAUKWLOSA-N 0.000 description 1
- 229940121386 matrix metalloproteinase inhibitor Drugs 0.000 description 1
- 239000003771 matrix metalloproteinase inhibitor Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 239000003475 metalloproteinase inhibitor Substances 0.000 description 1
- 206010061289 metastatic neoplasm Diseases 0.000 description 1
- 239000003094 microcapsule Substances 0.000 description 1
- 239000011859 microparticle Substances 0.000 description 1
- 210000000110 microvilli Anatomy 0.000 description 1
- 230000000394 mitotic effect Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 210000002200 mouth mucosa Anatomy 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 230000001338 necrotic effect Effects 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 230000010046 negative regulation of endothelial cell proliferation Effects 0.000 description 1
- 231100000956 nontoxicity Toxicity 0.000 description 1
- 238000011580 nude mouse model Methods 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 230000016087 ovulation Effects 0.000 description 1
- 239000006179 pH buffering agent Substances 0.000 description 1
- 230000036407 pain Effects 0.000 description 1
- 230000003076 paracrine Effects 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 230000009054 pathological process Effects 0.000 description 1
- 230000001991 pathophysiological effect Effects 0.000 description 1
- 230000010412 perfusion Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 229940024999 proteolytic enzymes for treatment of wounds and ulcers Drugs 0.000 description 1
- 102000037983 regulatory factors Human genes 0.000 description 1
- 108091008025 regulatory factors Proteins 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000002207 retinal effect Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 238000009097 single-agent therapy Methods 0.000 description 1
- 210000004927 skin cell Anatomy 0.000 description 1
- 208000000587 small cell lung carcinoma Diseases 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- ILJOYZVVZZFIKA-UHFFFAOYSA-M sodium;1,1-dioxo-1,2-benzothiazol-3-olate;hydrate Chemical compound O.[Na+].C1=CC=C2C(=O)[N-]S(=O)(=O)C2=C1 ILJOYZVVZZFIKA-UHFFFAOYSA-M 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 239000000021 stimulant Substances 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 230000003319 supportive effect Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000036962 time dependent Effects 0.000 description 1
- 231100000041 toxicology testing Toxicity 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- 210000005166 vasculature Anatomy 0.000 description 1
- 229960003048 vinblastine Drugs 0.000 description 1
- JXLYSJRDGCGARV-XQKSVPLYSA-N vincaleukoblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-XQKSVPLYSA-N 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/243—Platinum; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Inorganic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US1638796P | 1996-04-26 | 1996-04-26 | |
| US60/016,387 | 1996-04-26 | ||
| PCT/US1997/007011 WO1997040835A1 (en) | 1996-04-26 | 1997-04-25 | Treatment of carcinomas using squalamine in combination with other anti-cancer agents |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2000510460A true JP2000510460A (ja) | 2000-08-15 |
| JP2000510460A5 JP2000510460A5 (2) | 2004-12-09 |
Family
ID=21776862
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP09539076A Pending JP2000510460A (ja) | 1996-04-26 | 1997-04-25 | スクアラミンを他の抗癌剤と併用する上皮性悪性腫瘍の治療 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US6147060A (2) |
| EP (1) | EP0910382B1 (2) |
| JP (1) | JP2000510460A (2) |
| AT (1) | ATE242635T1 (2) |
| AU (1) | AU735884B2 (2) |
| CA (1) | CA2252584C (2) |
| DE (1) | DE69722793T2 (2) |
| DK (1) | DK0910382T3 (2) |
| ES (1) | ES2201296T3 (2) |
| PT (1) | PT910382E (2) |
| WO (1) | WO1997040835A1 (2) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2008514726A (ja) * | 2004-09-30 | 2008-05-08 | ザ ユニヴァーシティー オヴ シカゴ | ヘッジホッグ阻害剤、放射線及び化学療法薬の併用療法 |
Families Citing this family (78)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5847172A (en) * | 1995-06-07 | 1998-12-08 | Magainin Pharmaceuticals Inc. | Certain aminosterol compounds and pharmaceutical compositions including these compounds |
| WO2000009137A2 (en) * | 1998-08-12 | 2000-02-24 | Magainin Pharmaceuticals, Inc. | Aminosterol compounds and uses thereof |
| EP1119361A4 (en) * | 1998-09-10 | 2006-10-04 | Magainin Pharma | TREATMENT OF CARCINOMA WITH SQUALAMINE IN COMBINATION WITH OTHER ANTI-TUMOR AGENTS |
| HU229520B1 (en) * | 1999-02-12 | 2014-01-28 | Scripps Research Inst | Methods for treatment of tumors and metastases using a combination of anti-angiogenic and immuno therapies |
| US7820718B1 (en) | 1999-04-07 | 2010-10-26 | Roger Williams Hospital | Combinations of ceramide and chemotherapeutic agents for inducing cell death and uses thereof in treating cancer |
| ES2344831T3 (es) | 2000-06-23 | 2010-09-08 | Mitsubishi Tanabe Pharma Corporation | Potenciadores de un efecto antitumoral. |
| US20020073441A1 (en) | 2000-12-13 | 2002-06-13 | Ross Brian D. | Compositions and methods for detecting proteolytic activity |
| JP2005502653A (ja) * | 2001-08-20 | 2005-01-27 | トランセーヴ・インコーポレーテッド | 肺ガンの治療方法 |
| CA2457148A1 (en) * | 2001-08-20 | 2003-02-27 | Transave, Inc. | Treatment of cancers by inhalation of stable platinum-containing formulations |
| GB0126879D0 (en) * | 2001-11-08 | 2002-01-02 | Astrazeneca Ab | Combination therapy |
| WO2003075889A1 (en) * | 2002-03-05 | 2003-09-18 | Transave, Inc. | An inhalation system for prevention and treatment of intracellular infections |
| JP2006502233A (ja) * | 2002-08-02 | 2006-01-19 | トランセーブ，インク． | 白金凝集物およびその製造方法 |
| US9186322B2 (en) * | 2002-08-02 | 2015-11-17 | Insmed Incorporated | Platinum aggregates and process for producing the same |
| EP1581236B1 (en) * | 2002-10-29 | 2013-10-16 | Insmed Incorporated | Sustained release of antiinfectives |
| US7879351B2 (en) * | 2002-10-29 | 2011-02-01 | Transave, Inc. | High delivery rates for lipid based drug formulations, and methods of treatment thereof |
| US7718189B2 (en) | 2002-10-29 | 2010-05-18 | Transave, Inc. | Sustained release of antiinfectives |
| US20080194019A1 (en) * | 2003-09-09 | 2008-08-14 | Beth Israel Deaconess Medical Center, Inc. | Tumor Suppressor Lkb1 Kinase Directly Activates Amp-Activated Kinase |
| JP2007526322A (ja) * | 2004-03-02 | 2007-09-13 | マサチューセッツ インスティテュート オブ テクノロジー | ナノセル薬物送達系 |
| US20070053845A1 (en) * | 2004-03-02 | 2007-03-08 | Shiladitya Sengupta | Nanocell drug delivery system |
| WO2005089448A2 (en) * | 2004-03-18 | 2005-09-29 | Transave, Inc. | Administration of cisplatin by inhalation |
| CN101001633A (zh) * | 2004-05-21 | 2007-07-18 | 特兰萨夫公司 | 肺病和肺病前期病症的治疗 |
| US20060246124A1 (en) * | 2004-11-08 | 2006-11-02 | Pilkiewicz Frank G | Methods of treating cancer with lipid-based platinum compound formulations administered intraperitoneally |
| WO2006099445A2 (en) * | 2005-03-14 | 2006-09-21 | Massachusetts Institute Of Technology | Nanocells for diagnosis and treatment of diseases and disorders |
| ES2732251T3 (es) | 2005-04-25 | 2019-11-21 | Enterin Inc | Dilactato de escualamina cristalino |
| WO2006119211A2 (en) * | 2005-05-02 | 2006-11-09 | Genaera Corporation | Methods and compositions for treating ocular disorders |
| US20060283742A1 (en) * | 2005-06-16 | 2006-12-21 | Canel Lightning Co. Ltd. | Multi-lamp display packaging for lamps with collapsible lampshades |
| US9107824B2 (en) | 2005-11-08 | 2015-08-18 | Insmed Incorporated | Methods of treating cancer with high potency lipid-based platinum compound formulations administered intraperitoneally |
| WO2007056264A2 (en) * | 2005-11-08 | 2007-05-18 | Transave, Inc. | Methods of treating cancer with high potency lipid-based platinum compound formulations administered intraperitoneally |
| WO2007056263A2 (en) * | 2005-11-08 | 2007-05-18 | Transave, Inc. | Methods of treating cancer with high potency lipid-based platinum compound formulations administered intravenously |
| US20070190181A1 (en) * | 2005-11-08 | 2007-08-16 | Pilkiewicz Frank G | Methods of treating cancer with lipid-based platinum compound forumulations administered intravenously |
| US20070122350A1 (en) * | 2005-11-30 | 2007-05-31 | Transave, Inc. | Safe and effective methods of administering therapeutic agents |
| HUE029994T2 (en) | 2005-12-08 | 2017-04-28 | Insmed Inc | Lipid-based compositions of antiinfectives for treating pulmonary infections |
| AU2008224929A1 (en) * | 2007-03-14 | 2008-09-18 | Mayo Foundation For Medical Education And Research | Treating skin cancer |
| WO2008137717A1 (en) | 2007-05-04 | 2008-11-13 | Transave, Inc. | Compositions of multicationic drugs for reducing interactions with polyanionic biomolecules and methods and uses thereof |
| US9114081B2 (en) | 2007-05-07 | 2015-08-25 | Insmed Incorporated | Methods of treating pulmonary disorders with liposomal amikacin formulations |
| US9333214B2 (en) | 2007-05-07 | 2016-05-10 | Insmed Incorporated | Method for treating pulmonary disorders with liposomal amikacin formulations |
| US9119783B2 (en) | 2007-05-07 | 2015-09-01 | Insmed Incorporated | Method of treating pulmonary disorders with liposomal amikacin formulations |
| US9611313B2 (en) * | 2007-06-26 | 2017-04-04 | University Of Miami | Antibody-endostatin fusion protein and its variants |
| RU2365370C1 (ru) * | 2008-04-29 | 2009-08-27 | Государственное учреждение Российский онкологический научный центр им. Н.Н. Блохина РАМН | Способ лечения рака легкого |
| RU2367436C1 (ru) * | 2008-05-26 | 2009-09-20 | Государственное учреждение Российский онкологический научный центр им. Н.Н. Блохина РАМН | Способ лечения рака легкого |
| WO2010003057A2 (en) | 2008-07-03 | 2010-01-07 | Mayo Foundation For Medical Education And Research | Treating cancer |
| RU2388503C1 (ru) * | 2008-08-14 | 2010-05-10 | Федеральное государственное учреждение "Ростовский научно-исследовательский онкологический институт Росмедтехнологий" | Способ лечения рака легкого |
| RU2402280C2 (ru) * | 2008-12-01 | 2010-10-27 | Федеральное государственное учреждение "Российский научно-исследовательский онкологический институт Росмедтехнологий" | Способ прогнозирования церебральных метастазов рака легкого |
| RU2406452C1 (ru) * | 2009-06-22 | 2010-12-20 | Федеральное государственное учреждение "Ростовский научно-исследовательский онкологический институт Росмедтехнологий" | Способ лечения рака легкого |
| RU2414894C1 (ru) * | 2009-06-29 | 2011-03-27 | Учреждение Российской академии медицинских наук Российский онкологический научный центр имени Н.Н. Блохина РАМН | Способ лечения рака легкого |
| WO2011056650A2 (en) | 2009-10-27 | 2011-05-12 | Michael Zasloff | Methods and compositions for treating and preventing viral infections |
| WO2011066260A2 (en) * | 2009-11-25 | 2011-06-03 | Michael Zasloff | Formulations comprising aminosterols |
| RU2411018C1 (ru) * | 2009-12-22 | 2011-02-10 | Государственное образовательное учреждение высшего профессионального образования "БАШКИРСКИЙ ГОСУДАРСТВЕННЫЙ МЕДИЦИНСКИЙ УНИВЕРСИТЕТ ФЕДЕРАЛЬНОГО АГЕНТСТВА ПО ЗДРАВООХРАНЕНИЮ И СОЦИАЛЬНОМУ РАЗВИТИЮ" | Способ локальной химиотерапии метастазов в печень |
| RU2429842C1 (ru) * | 2010-06-15 | 2011-09-27 | Учреждение Российской академии медицинских наук Научно-исследовательский институт онкологии Сибирского отделения Российской академии медицинских наук (НИИ онкологии СО РАМН) | Способ профилактики послеоперационных осложнений при комбинированном лечении больных немелкоклеточным раком легкого iii стадии |
| PT2707030T (pt) | 2011-05-09 | 2020-05-22 | Mayo Found Medical Education & Res | Tratamentos de cancro |
| HUE039389T2 (hu) * | 2012-03-30 | 2019-01-28 | Univ California | Az anti-EMP2 terápia csökkenti a rák õssejteket |
| US10385395B2 (en) | 2012-04-11 | 2019-08-20 | The Regents Of The University Of California | Diagnostic tools for response to 6-thiopurine therapy |
| MX369828B (es) | 2012-05-21 | 2019-11-22 | Insmed Inc | Sistemas para tratar infecciones pulmonares. |
| CN121606602A (zh) | 2012-09-04 | 2026-03-06 | 埃莱森制药股份有限公司 | 用顺铂脂质复合物预防癌症的肺部复发 |
| US10413606B2 (en) | 2012-10-01 | 2019-09-17 | Mayo Foundation For Medical Education And Research | Methods for treating cancer with nanoparticle complexes of albumin-bound paclitaxel and anti-VEGF antibodies |
| RU2018135921A (ru) | 2012-11-29 | 2019-02-05 | Инсмед Инкорпорейтед | Стабилизированные составы ванкомицина |
| US10040817B2 (en) | 2013-10-03 | 2018-08-07 | Enterin Laboratories, Inc. | Methods and compositions for stimulation of the intestinal enteroendocrine system for treating diseases or conditions related to the same |
| SMT202000516T1 (it) | 2014-05-15 | 2020-11-10 | Insmed Inc | Metodi per trattamento di infezioni micobatteriche polmonati non tubercolari |
| US20160250351A1 (en) | 2014-06-13 | 2016-09-01 | Mayo Foundation For Medical Education And Research | Treating Lymphomas |
| EP3834889A1 (en) | 2014-06-16 | 2021-06-16 | Mayo Foundation for Medical Education and Research | Treating myelomas |
| US9446148B2 (en) | 2014-10-06 | 2016-09-20 | Mayo Foundation For Medical Education And Research | Carrier-antibody compositions and methods of making and using the same |
| TW201707725A (zh) | 2015-08-18 | 2017-03-01 | 美國馬友醫藥教育研究基金會 | 載體－抗體組合物及其製造及使用方法 |
| TW201713360A (en) | 2015-10-06 | 2017-04-16 | Mayo Foundation | Methods of treating cancer using compositions of antibodies and carrier proteins |
| WO2017120501A1 (en) | 2016-01-07 | 2017-07-13 | Mayo Foundation For Medical Education And Research | Methods of treating cancer with interferon |
| WO2017139698A1 (en) | 2016-02-12 | 2017-08-17 | Mayo Foundation For Medical Education And Research | Hematologic cancer treatments |
| US11305020B2 (en) | 2016-03-21 | 2022-04-19 | Mayo Foundation For Medical Education And Research | Methods for reducing toxicity of a chemotherapeutic drug |
| EP3432928A4 (en) | 2016-03-21 | 2019-11-20 | Mayo Foundation for Medical Education and Research | PROCESS FOR IMPROVING THE THERAPEUTIC INDEX FOR CHEMOTHERAPEUTIC |
| US10618969B2 (en) | 2016-04-06 | 2020-04-14 | Mayo Foundation For Medical Education And Research | Carrier-binding agent compositions and methods of making and using the same |
| CA3035377A1 (en) | 2016-09-01 | 2018-03-08 | Mayo Foundation For Medical Education And Research | Nanoparticle compositions for targeting t-cell cancers |
| CN109890419A (zh) | 2016-09-01 | 2019-06-14 | 梅约医学教育与研究基金会 | 用于治疗癌症的载体-pd-l1结合剂组合物 |
| EP3509643A1 (en) | 2016-09-06 | 2019-07-17 | Mayo Foundation for Medical Education and Research | Paclitaxel-albumin-binding agent compositions and methods for using and making the same |
| WO2018048816A1 (en) | 2016-09-06 | 2018-03-15 | Mayo Foundation For Medical Education And Research | Methods of treating pd-l1 expressing cancer |
| US11590098B2 (en) | 2016-09-06 | 2023-02-28 | Mayo Foundation For Medical Education And Research | Methods of treating triple-negative breast cancer using compositions of antibodies and carrier proteins |
| MA50094A (fr) | 2017-09-08 | 2020-07-15 | Enterin Inc | Méthodes de traitement des troubles du sommeil, des perturbations du sommeil et de symptômes associés à l'aide de compositions d'aminostérol |
| WO2019089603A1 (en) * | 2017-10-31 | 2019-05-09 | Dana-Farber Cancer Institute, Inc. | Methods for determining and treating cellular resistance to adp-ribosylating toxin |
| EP3773505B1 (en) | 2018-03-30 | 2026-04-29 | Insmed Incorporated | Methods for continuous manufacture of liposomal drug products |
| WO2019213398A1 (en) | 2018-05-02 | 2019-11-07 | Insmed Incorporated | Methods for the manufacture of liposomal drug formulations |
| CN116407640B (zh) * | 2023-03-03 | 2025-10-31 | 河南真实生物科技有限公司 | 包含阿兹夫定和化疗试剂的抗肿瘤药物组合物 |
Family Cites Families (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3016390A (en) * | 1960-06-30 | 1962-01-09 | Searle & Co | N-(substituted alkyl) amino-5alpha-androstan-17beta-ols |
| US3370070A (en) * | 1965-06-16 | 1968-02-20 | Searle & Co | [n-alkyl-17-(dialkylaminoalkyl)amino] androst-4-en-3-ones |
| GB1565351A (en) * | 1975-06-02 | 1980-04-16 | Theramex | Steroid aminoethers |
| US4220598A (en) * | 1977-11-14 | 1980-09-02 | Abbott Laboratories | Method and reagents for measuring the level of conjugated bile acids |
| US4550163A (en) * | 1979-02-05 | 1985-10-29 | Abbott Laboratories | Ligand analog-irreversible enzyme inhibitor conjugates |
| US4372888A (en) * | 1980-08-26 | 1983-02-08 | The United States Of America As Represented By The Secretary Of The Department Of Health & Human Services | Nondenaturing zwitterionic detergents |
| JPS5842878B2 (ja) * | 1981-12-02 | 1983-09-22 | 名糖産業株式会社 | １２−オキソコラン酸トシルヒドラゾン化合物、その製法ならびに利用 |
| DE3366932D1 (en) * | 1982-07-29 | 1986-11-20 | Lehner Ag | New derivatives of biliary acids, process for the production thereof and pharmaceutical compositions containing the same |
| US5001116A (en) * | 1982-12-20 | 1991-03-19 | The Children's Medical Center Corporation | Inhibition of angiogenesis |
| US4994443A (en) * | 1982-12-20 | 1991-02-19 | The Children's Medical Center Corporation | Inhibition of angiogenesis |
| IT1221734B (it) * | 1983-02-24 | 1990-07-12 | Schiena Michele Giuseppe Di | Ursodesossicolico solfato acido sale sodico |
| US4545938A (en) * | 1983-11-02 | 1985-10-08 | Beth Israel Medical Center | Chemical synthesis |
| JPS6133121A (ja) * | 1984-07-25 | 1986-02-17 | Nissei Marine Kogyo Kk | 制癌剤 |
| WO1987002367A2 (en) * | 1985-10-18 | 1987-04-23 | The Upjohn Company | Cyclic hydrocarbons with an aminoalkyl sidechain |
| US4771042A (en) * | 1985-11-25 | 1988-09-13 | The Upjohn Company | Inhibition of angiogenesis involving the coadministration of steroids with heparin or heparin fragments |
| JPS62175497A (ja) * | 1986-01-28 | 1987-08-01 | Wakunaga Pharmaceut Co Ltd | 胆汁酸誘導体およびその製造法 |
| US5075464A (en) * | 1987-04-22 | 1991-12-24 | Merrell Dow Pharmaceuticals Inc. | 17β-(cyclopropylamino)androstene derivatives |
| SE8702254D0 (sv) * | 1987-05-29 | 1987-05-29 | Kabivitrum Ab | Novel heparin derivatives |
| US5135919A (en) * | 1988-01-19 | 1992-08-04 | Children's Medical Center Corporation | Method and a pharmaceutical composition for the inhibition of angiogenesis |
| IT1229570B (it) * | 1989-04-17 | 1991-09-04 | Giuliani Spa | Derivati fluorurati di acidi biliari, loro preparazione e composizioni farmaceutiche che li contengono. |
| IT1229569B (it) * | 1989-04-17 | 1991-09-04 | Giuliani Spa | Derivati di acidi biliari, loro preparazione e composizioni farmaceutiche che li contengono. |
| JPH07116215B2 (ja) * | 1989-04-19 | 1995-12-13 | エスエス製薬株式会社 | 新規なステロイド化合物 |
| PT93847A (pt) * | 1989-04-24 | 1990-11-20 | Harvard College | Processo para a preparacao de oligossacaridos de baixo peso molecular derivados de heparina ou de sulfato de heparano despolimerizados e de composicoes farmaceuticas que os contem |
| US4966897A (en) * | 1989-08-15 | 1990-10-30 | Merrell Dow Pharmaceuticals Inc. | 4-substituted 17β-(cyclopropyloxy)androst-5-en-3β-ol and related compounds useful as C17-20 lyase inhibitors |
| US5004737A (en) * | 1989-09-22 | 1991-04-02 | Pacific Chemical Co., Ltd. | Quaternary ammonium-substituted sterol derivatives |
| EP0466315A3 (en) * | 1990-05-30 | 1992-07-01 | Larrian Gillespie | Compositions containing xylan sulphates for affecting growth factor function and for inhibiting fibroblast proliferation |
| WO1991019731A1 (en) * | 1990-06-11 | 1991-12-26 | The Upjohn Company | Steroids which inhibit angiogenesis |
| NZ240846A (en) * | 1990-12-06 | 1994-04-27 | Hoechst Ag | Dimeric bile acid derivatives; preparatory processes and pharmaceutical compositions |
| US5192756A (en) * | 1992-03-18 | 1993-03-09 | The Children's Hospital Of Pennsylvania | Aminosterol antibiotic |
| WO1993025197A1 (en) * | 1992-06-12 | 1993-12-23 | Affymax Technologies N.V. | Compositions and methods for enhanced drug delivery |
| WO1994019366A1 (en) * | 1993-02-26 | 1994-09-01 | Magainin Pharmaceuticals Inc. | Chemical synthesis of squalamine |
| DE69412596T2 (de) * | 1993-03-10 | 1999-03-04 | Magainin Pharmaceuticals Inc., Plymouth Meeting, Pa. | Steroidderivate, pharmazeutische zusammensetzungen die sie enthalten und ihre verwendung als antibiotika oder desinfektionsmittel |
| JPH09509959A (ja) * | 1994-03-10 | 1997-10-07 | マガイニン ファーマシューティカルズ インク． | ステロイド誘導体、それらを含む薬剤組成物、及びそれらの薬剤学的用途 |
| US5792635A (en) * | 1995-06-07 | 1998-08-11 | Magainin Pharmaceuticals, Inc. | Method of inhibiting the sodium/proton exchanger NHE3 and method of inhibiting growth by administering squalamine |
| ATE259375T1 (de) * | 1995-06-07 | 2004-02-15 | Genaera Corp | Aminosterinverbindungen als inhibitoren der natrium/proton-pump, pharmazeutische methoden und präparaten davon |
-
1997
- 1997-04-25 ES ES97921396T patent/ES2201296T3/es not_active Expired - Lifetime
- 1997-04-25 WO PCT/US1997/007011 patent/WO1997040835A1/en not_active Ceased
- 1997-04-25 AT AT97921396T patent/ATE242635T1/de not_active IP Right Cessation
- 1997-04-25 AU AU27441/97A patent/AU735884B2/en not_active Ceased
- 1997-04-25 PT PT97921396T patent/PT910382E/pt unknown
- 1997-04-25 CA CA002252584A patent/CA2252584C/en not_active Expired - Lifetime
- 1997-04-25 EP EP97921396A patent/EP0910382B1/en not_active Expired - Lifetime
- 1997-04-25 US US08/840,706 patent/US6147060A/en not_active Expired - Lifetime
- 1997-04-25 DE DE69722793T patent/DE69722793T2/de not_active Expired - Lifetime
- 1997-04-25 DK DK97921396T patent/DK0910382T3/da active
- 1997-04-25 JP JP09539076A patent/JP2000510460A/ja active Pending
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2008514726A (ja) * | 2004-09-30 | 2008-05-08 | ザ ユニヴァーシティー オヴ シカゴ | ヘッジホッグ阻害剤、放射線及び化学療法薬の併用療法 |
Also Published As
| Publication number | Publication date |
|---|---|
| CA2252584A1 (en) | 1997-11-06 |
| DE69722793T2 (de) | 2004-05-19 |
| AU2744197A (en) | 1997-11-19 |
| ATE242635T1 (de) | 2003-06-15 |
| US6147060A (en) | 2000-11-14 |
| ES2201296T3 (es) | 2004-03-16 |
| DK0910382T3 (da) | 2003-10-06 |
| PT910382E (pt) | 2003-10-31 |
| CA2252584C (en) | 2008-06-10 |
| EP0910382B1 (en) | 2003-06-11 |
| EP0910382A1 (en) | 1999-04-28 |
| DE69722793D1 (de) | 2003-07-17 |
| WO1997040835A1 (en) | 1997-11-06 |
| AU735884B2 (en) | 2001-07-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2000510460A (ja) | スクアラミンを他の抗癌剤と併用する上皮性悪性腫瘍の治療 | |
| US6596712B2 (en) | Treatment of carcinomas using squalamine in combination with other anti-cancer agents or modalities | |
| KR101925436B1 (ko) | 암 치료를 위한 종양 저 산소 상태의 유도 | |
| US10864229B2 (en) | Use of nitrite salts in chronic ischemia | |
| US20190022225A1 (en) | Protocol for increasing life expectancy in a test subject | |
| JP2003505506A (ja) | 幹細胞と前駆細胞のリクルートメントにおけるニコチン受容体アゴニスト | |
| CN105792845A (zh) | 使用低氧活化的前药与紫杉烷类化合物的组合治疗胰腺癌 | |
| EP1480627A4 (en) | Methods of reducing angiogenesis | |
| EP3154551A1 (en) | The use of dextran sulfate having an average molecular weight below 10000 da for inducing angiogenisis in a subject | |
| JP2025520608A (ja) | 癌を治療するための組成物、システム、および方法、腫瘍治療場およびｖｅｇｆ阻害剤 | |
| Andrew et al. | The Use of Lipid-coated Microbubbles as a Delivery Agent of 7/3-Hydroxycholesterol in a Radiofrequency Lesion in the Rat Brain | |
| WO2015190989A1 (en) | The use of dextran sulfate having an average molecular weight below 10000 da for inducing angiogenisis in a subject | |
| US7018979B1 (en) | Method for using potassium channel agonists for delivering a medicant to an abnormal brain region and/or a malignant tumor | |
| KR20040004681A (ko) | 혈관재생 요법 | |
| WO2009048953A1 (en) | Thrombopoietin receptor agonist (tpora) kills acute human myeloid leukemia cells | |
| CN115997122A (zh) | 类维生素a与癌治疗剂的组合疗法有效的癌患者的选择方法、及类维生素a与癌治疗剂的组合药物 | |
| AU757649B2 (en) | Treatment of carcinomas using squalamine in combination with other anti-cancer agents or modalities | |
| CN109069478B (zh) | Z-亚丁基苯酞于活化自体免疫系统的应用 | |
| US8106009B2 (en) | Pharmaceutical composition for preventing or treating ischemic diseases | |
| JP2002524481A5 (2) | ||
| AU2003200309B2 (en) | Pharmaceutical Composition for Preventing or Treating Ischaemic Diseases | |
| Ribatti | Anti-angiogenesis | |
| KR20210091054A (ko) | 항암 화학요법으로 인한 내성을 완화하고 항암 화학요법의 효과를 증진시키기 위한 약학적 조성물 및 그 용도 | |
| WO2002089807A1 (en) | Timing and duration of administration of adenosine a1/a2 agonist for cardioprotection | |
| HK1152657A (en) | Use of nitrite salts in chronic ischemia |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20040409 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20040409 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20080115 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20080403 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20080519 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20080507 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20080616 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20080604 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20080714 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20080715 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20081028 |